Lily Allen returned to the Saturday Night Live stage after nearly 19 years away with two performances from her latest pop album, West End Girl. Allen, an SNL musical guest in early 2007, opened with ...
Lily Allen is headed out on tour to promote her controversial, cult favorite album "West End Girl." The British singer, 40, will criss-cross North America for her biggest tour yet, beginning in Spring ...
Shares of Eli Lilly and Co (NYSE:LLY) are sliding into the red, down 0.8% to trade at $1,066.96 at last check, amid news the pharma giant cut prices on popular weight loss drug Zepbound. The ...
Eli Lilly (LLY) officially joined the elite group of U.S. companies valued at more than $1T on Friday, becoming the tenth American stock to currently cross the landmark threshold. The move came as ...
Anthony Mason is a senior culture and senior national correspondent for CBS News. He has been a frequent contributor to "CBS Sunday Morning." Vice President of Growth & Engagement at CBS News and ...
Fintel reports that on November 12, 2025, Citigroup maintained coverage of Eli Lilly and (NYSE:LLY) with a Buy recommendation. Analyst Price Forecast Suggests 8.95% Downside As of November 9, 2025, ...
Nvidia (NVDA) may post sales of $56.8B next week according to Citi. Multiple firms upgraded their price targets ahead of earnings. Sunrun (RUN) was upgraded to buy by Guggenheim with a $27 price ...
Hosted on MSN
Leerink Partners Upgrades Eli Lilly and (LLY)
Fintel reports that on November 10, 2025, Leerink Partners upgraded their outlook for Eli Lilly and (NYSE:LLY) from Market Perform to Outperform. Analyst Price Forecast Suggests 0.26% Upside As of ...
Eli Lilly's Mounjaro and Zepbound deliver accelerated weight loss rates compared to Novo Nordisk's Wegovy, which perhaps explains the former's triple-digit GLP-1 revenue growth on a YoY basis. This is ...
Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Rising Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is seen as a strong healthcare stock that investors can ...
Eli Lilly stock (NYSE: LLY) is up 10% this month, a rise driven by strong clinical trial progress. This includes the announcement of positive Phase 3 results in October 2025 for its oral GLP-1 drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback